Pyrvinium
Povan (pyrvinium) is a small molecule pharmaceutical. Pyrvinium was first approved as Povan on 1982-01-01.
Download report
Favorite
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
HCPCS
No data
Clinical
Clinical Trials
155 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Malaria | D008288 | EFO_0001068 | B54 | 10 | 13 | 35 | 22 | 25 | 95 |
| Falciparum malaria | D016778 | EFO_0007444 | B50 | 1 | 5 | 9 | 3 | 8 | 23 |
| Anemia | D000740 | EFO_0004272 | D64.9 | — | — | 4 | 3 | 8 | 15 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 3 | 3 | 2 | 1 | 6 | 14 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | — | 5 | 1 | 4 | 10 |
| Hiv | D006678 | O98.7 | 1 | — | — | 1 | — | 2 | |
| Toxoplasmosis | D014123 | EFO_0007517 | B58 | 1 | — | — | 1 | — | 2 |
| Acquired immunodeficiency syndrome | D000163 | EFO_0000765 | B20 | — | — | — | 2 | — | 2 |
| Treatment adherence and compliance | D000074822 | — | — | — | 1 | — | 1 | ||
| Pharmacokinetics | D010599 | — | — | — | 1 | — | 1 |
Show 3 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Vivax malaria | D016780 | EFO_0007445 | B51 | — | 1 | 2 | — | 2 | 5 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | 1 | 1 | 1 | — | — | 2 |
| Sexually transmitted diseases | D012749 | A50-A64 | — | — | 2 | — | — | 2 | |
| Healthy volunteers/patients | — | 1 | — | 1 | — | — | 2 | ||
| Schistosoma mansoni | D012550 | NCBITaxon_6183 | — | — | 1 | — | — | 1 | |
| Asymptomatic diseases | D058070 | — | — | 1 | — | — | 1 | ||
| Respiratory tract infections | D012141 | J06.9 | — | — | 1 | — | — | 1 | |
| Premature birth | D047928 | EFO_0003917 | O60 | — | — | 1 | — | — | 1 |
| Chorioretinitis | D002825 | HP_0012424 | H30 | — | — | 1 | — | — | 1 |
| Bacterial vaginosis | D016585 | EFO_0003932 | — | — | 1 | — | — | 1 |
Show 5 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral toxoplasmosis | D016781 | EFO_0007200 | B58.2 | 2 | 2 | — | — | 3 | 7 |
| Tay-sachs disease | D013661 | Orphanet_845 | E75.02 | 2 | 1 | — | — | — | 2 |
| Sandhoff disease | D012497 | Orphanet_796 | E75.01 | 2 | 1 | — | — | — | 2 |
| Gm2 gangliosidoses | D020143 | Orphanet_309152 | E75.0 | 2 | 1 | — | — | — | 2 |
| Cardiotoxicity | D066126 | EFO_1001482 | — | 1 | — | — | — | 1 | |
| Parasitemia | D018512 | — | 1 | — | — | — | 1 | ||
| Amyotrophic lateral sclerosis | D000690 | EFO_0000253 | G12.21 | 1 | 1 | — | — | — | 1 |
| B-cell chronic lymphocytic leukemia | D015451 | C91.1 | 1 | 1 | — | — | — | 1 | |
| Lymphoid leukemia | D007945 | C91 | 1 | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Lymphoproliferative disorders | D008232 | Orphanet_2442 | D47.9 | 2 | — | — | — | — | 2 |
| Autoimmune diseases | D001327 | EFO_0000540 | M30-M36 | 2 | — | — | — | — | 2 |
| Myelodysplastic syndromes | D009190 | D46 | 1 | — | — | — | — | 1 | |
| Lymphatic diseases | D008206 | HP_0100763 | 1 | — | — | — | — | 1 | |
| Head and neck neoplasms | D006258 | 1 | — | — | — | — | 1 | ||
| Therapeutic equivalency | D013810 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fever | D005334 | HP_0001945 | R50.9 | — | — | — | — | 1 | 1 |
| Birth weight | D001724 | EFO_0004344 | — | — | — | — | 1 | 1 | |
| Infections | D007239 | EFO_0000544 | — | — | — | — | 1 | 1 | |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | — | — | 1 | 1 |
| Schistosomiasis | D012552 | EFO_1001475 | B65 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | PYRVINIUM |
| INN | pyrvinium chloride |
| Description | Pyrvinium pamoate is a naphthoic acid. It has a role as an anticoronaviral agent. |
| Classification | Small molecule |
| Drug class | quaternary ammonium derivatives; vinca alkaloids |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | Cc1cc(/C=C/c2ccc3cc(N(C)C)ccc3[n+]2C)c(C)n1-c1ccccc1 |
Identifiers
| PDB | — |
| CAS-ID | 3546-41-6 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201303 |
| ChEBI ID | 8687 |
| PubChem CID | 54680693 |
| DrugBank | — |
| UNII ID | MT7O310S39 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
No data
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 924 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
1,114 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more